Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences Inc (CSTL)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Portolan Capital Management George Mccabe | 1,043,410 | $23,111,532 | +44% | 1.76% |
| 2. | Deerfield Management James E. Flynn | 928,017 | $20,555,577 | -4% | 0.35% |
| 3. | Soleus Capital Guy Levy | 725,457 | $16,068,873 | +2691% | 1.19% |
| 4. | Citadel Investment Group Ken Griffin | 655,766 | $14,525,217 | +100% | 0% |
| 5. | Parkman Healthcare Partners Greg Martinez | 367,408 | $8,138,087 | +3% | 0.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.27 | 2,500 | Director | 9,065 | 2023-06-05 | Filing | |
| $11.23 | 2,300 | Director | 6,565 | 2023-06-05 | Filing | |
| $21.50 | 1,162 | Director | 2,968 | 2022-11-29 | Filing | |
| $18.77 | 220 | Director | 1,806 | 2022-05-12 | Filing | |
| $18.76 | 1,100 | Director | 1,586 | 2022-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.22 | 2,793 | Officer | 148,618 | 2024-07-01 | Filing | |
| $23.98 | 6 | Officer, Director | 8,525 | 2024-06-03 | Filing | |
| $23.98 | 6 | Officer, Director | 8,525 | 2024-06-03 | Filing | |
| $23.98 | 6 | Officer, Director | 8,525 | 2024-06-03 | Filing | |
| $23.98 | 6 | Officer, Director | 8,527 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,590,951 | $55,912,723 | 0.3% | |
| 2. | 2,283,199 | $49,271,436 | 0% | |
| 3. | 2,166,471 | $46,752,444 | 1.54% | |
| 4. | 1,585,673 | $34,218,823 | 0.02% | |
| 5. | 1,461,481 | $31,538,760 | 0% |
News See All
What Makes Castle Bioscience (CSTL) a Prospective Investment?
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds released “The RiverPark/Next Century Growth Fund” Q4 2023 investor letter in partnership with Next...
Does Castle Bioscience (CSTL) Have Robust Growth Prospects?
Next Century Growth Investors, LLC, an investment Management Company, released its “SMID Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2023 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Second Quarter 2023 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2023 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter 2022 Conference Call. As a reminder, today's call is being recorded.
Is it Still Safe to Invest in Castle Biosciences (CSTL)?
Wasatch Global Investors, an investment management firm, published its "Wasatch Micro Cap Fund" fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
